Cipla's subsidiary InvaGen received zero Form 483 observations in a routine USFDA cGMP inspection. The clean outcome confirms compliance at its US manufacturing facility.
Cipla reported receiving seven inspectional observations from the USFDA following a cGMP inspection at its Pithampur facility. The company intends to address these observations promptly.
Cipla announced that its subsidiary, InvaGen, received the Establishment Inspection Report from the USFDA, officially closing the inspection of its Hauppauge facility.